Trial Profile

Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RAPA 501 (Primary)
Indications COVID-19 respiratory infection
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Rapa Therapeutics

Most Recent Events

03 Nov 2021 Status changed from recruiting to discontinued.
16 Dec 2020 Status changed from not yet recruiting to recruiting.
05 Nov 2020 Planned End Date changed from 28 Feb 2022 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com